HIV associated eosinophilic folliculitis—
differential diagnosis and management

Sara L Simpson-Dent, Louise A Fearfield, Richard C D Staughton

Eosinophilic folliculitis (EF) is a chronic, intensely pruritic condition of unknown pathogenesis that causes marked morbidity in those HIV patients whom it affects. There is a wide differential diagnosis of itchy skin conditions in HIV which are amenable to different treatments. It is therefore essential to take a biopsy of each suspected case and examine multiple sections of the biopsy to confirm or refute a diagnosis of EF. Treatment of EF can be difficult but we hope that by suggesting a rational approach to this and considering possible therapeutic options more patients may be helped with this troublesome dermatosis.

(Sex Transm Infect 1999; 75:291–293)

Keywords: eosinophilic folliculitis; HIV

Introduction
Eosinophilic pustular folliculitis was originally described by Ofuji et al.1 It was not until 1986 that it was first recognised to occur in the human immunodeficiency virus (HIV) infected population.2 In this group it is now referred to as HIV associated eosinophilic folliculitis (EF) as it shows differences from the original Japanese description in its distribution, appearance of lesions, disease course, and symptoms. EF is not unique to HIV as it has rarely been described in association with haematological malignancies.3

Clinical picture
Patients affected by EF classically complain of a persistent pruritic rash. The intensity of the itch is akin to that of scabies and patients excoriate deeply. Clinically, one can see 2–3 mm erythematous papules or pustules, most frequently affecting the shoulders, trunk, upper arms, neck and forehead, where it can be disfiguring (fig 1). Less commonly, other areas of the body are affected but EF is only rarely generalised. Lesions are follicular and are often markedly excoriated, making it difficult to determine their nature. It is therefore important to look for fresh unexcoriated lesions. There are no associated systemic features but patients are often tired and irritable.

EF is quite common, occurring in HIV infected individuals with a CD4 count of less than 250 × 10⁶/l with an incidence, in one series, of 9%.4 Up to 50% of sufferers will have a peripheral eosinophilia, up to 4 × 10⁹/l in our series and their IgE is often also elevated.

Differential diagnosis
Clinically the differential diagnosis of EF is between the infective folliculitides or other dermatoses that may or may not be HIV related—for example, scabies, urticaria, drug rashes, and eczema. Clues in the history and the examination can help refine the diagnosis (table 1). Of note we feel that it is inappropriate to make a diagnosis of papular eruption of HIV as most cases will turn out to be EF if investigated appropriately.
Table 1  Ways of obtaining diagnosis of eosinophilic folliculitis

<table>
<thead>
<tr>
<th>Differential diagnosis</th>
<th>Clues in history and examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infestations:</td>
<td></td>
</tr>
<tr>
<td>Scabies</td>
<td>Nighttime itching</td>
</tr>
<tr>
<td></td>
<td>Partner itching</td>
</tr>
<tr>
<td></td>
<td>Genital and web space lesions present</td>
</tr>
<tr>
<td>Papular urticaria</td>
<td>Crops of linearly arranged papules</td>
</tr>
<tr>
<td>(insect bite reactions)</td>
<td>Pets at home, hostel accommodation, or of no fixed abode</td>
</tr>
<tr>
<td></td>
<td>?Lice on seams of patient’s clothes</td>
</tr>
<tr>
<td>Atoxic:</td>
<td></td>
</tr>
<tr>
<td>Urticaria</td>
<td>Individual weals lasting 6–12 hours</td>
</tr>
<tr>
<td>Eczema</td>
<td>?Family or personal history of atopy</td>
</tr>
<tr>
<td>Generalised rash</td>
<td>New drug within past 10–14 days</td>
</tr>
<tr>
<td>Iatrogenic:</td>
<td></td>
</tr>
<tr>
<td>Drug rash</td>
<td>Generalised rash</td>
</tr>
<tr>
<td>Other:</td>
<td></td>
</tr>
<tr>
<td>Nodular prurigo</td>
<td>Nodular rather than papular lesions lasting months/years</td>
</tr>
<tr>
<td>Lichen planus/nitidus</td>
<td>Flat topped purple papules with Wickham’s striae</td>
</tr>
</tbody>
</table>

Short term management

(1) Biopsy, then while awaiting result:
(2) Topical steroid—for example, 0.1% betamethasone valerate ointment
(3) Antihistamine—for example, cetirizine 20–40 mg daily

Long term management

4 week trial of itraconazole 200 mg once daily
or metronidazole 250 mg three times daily
or referral to a dermatologist for ultraviolet B 2–3 times/week to clearance
or isotretinoin 20–40 mg daily for 4–6 weeks

Histology of EF

The histology of EF shows an inflammatory infiltrate, predominantly of eosinophils and lymphocytes which is folliculocentric with marked sebaceous lysis (fig. 2). This is distinct from infective causes of folliculitis—for example, Gram positive cocci, demodex, and pityrosporum when micro-organisms are seen within the inflammatory infiltrate (macrophages and neutrophils). The affected follicle is frequently ruptured in a bacterial folliculitis. The histopathologist should be asked to take multiple serial sections of the EF biopsy as otherwise the affected follicle may be missed and the incorrect diagnosis made.

Pathogenesis of EF

The pathogenesis of EF is unknown but, owing to the folliculocentric nature of the inflammation, an opportunistic infection has been proposed although no one organism has consistently been isolated in biopsy specimens. Fungi, yeasts, demodex, and bacteria have all at times been seen and implicated. Other theories are of a follicular hypersensitivity reaction or an autoimmune reaction to sebum (L A Fearfield, in preparation).

Treatment of EF

Treatment of EF is difficult and varied because the underlying pathogenic mechanism of EF still remains to be elucidated. Treatments tried have included topical steroids, topical ascarides—for example, permethrin, phototherapy (ultraviolet A and B light), itraconazole, isotretinoin, and metronidazole. All have had reported successes but the series reported have tended to be of small size and anecdotal rather than controlled or randomised. We discuss the different modalities below and our recommendations for treatment are shown in table 2.

TOPICAL STEROIDS
These can give partial temporary symptomatic relief but new lesions continue to crop up. For example, 0.1% betamethasone valerate (Betnovate, Glaxo), can be useful as a temporary measure when awaiting the results of the biopsy.

ANTIHISTAMINES
The anti-eosinophilic cetirizine (Zirtek, Schering-Plough) gives modest symptomatic relief especially if higher than usual dosages are used—for example, 20–40 mg daily in divided doses.

ULTRAVIOLET B PHOTOTHERAPY
Patients often report an improvement in symptoms after sunny holidays abroad and ultraviolet B is established as an effective treatment. Patients mostly respond to thrice weekly broad band ultraviolet B within 3–6 weeks. Relapse is frequent and weekly maintenance ultraviolet B may be needed. Ultraviolet B exerts an immunosuppressive effect on the skin and herpes simplex virus is reactivated in some. Earlier fears of accelerating progression of HIV disease have not been borne out.

ITRACONAZOLE
It has been suggested, by some authors, that fungi or yeasts—for example, *Pityrosporum ovale* may be involved in the pathogenesis of EF. This is certainly supported by the response of EF to oral itraconazole. In one study, by Berger *et al*, of 28 patients 74% showed initial complete or partial response to oral itraconazole. At 3 months five remained clear of lesions, two required topical steroids only, and 12 were controlled (n=8) or partly controlled with oral itraconazole. It is suggested that itraconazole is started at a dose of 200 mg daily. A response is normally seen within the first 2 weeks but if this has not occurred or the response is incomplete then the dose may be increased to 300 mg or 400 mg daily although the incidence of side effects is then increased. Maintenance therapy may be necessary. Fluconazole is not a substitute for itraconazole as patients changed to this drug relapsed.
METRONIDAZOLE
Metronidazole 250 mg three times daily for 4 weeks was reported to be effective in clearing EF in five out of five patients initially and following any subsequent relapse. This followed the finding of a Gram negative organism on one of the patient’s biopsies.

ISOTRETINOIN
In an initial study in 1995 all of the seven patients treated demonstrated a complete response within 1–4 weeks of starting isotretinoin treatment at a dose of 40–80 mg/day (higher doses were given for those patients who were more severely affected). Any relapses responded to repeat courses of isotretinoin. (It must be remembered that isotretinoin is teratogenic and therefore should be used only with extreme caution in women of childbearing age.)

In our experience it is a very effective and well tolerated treatment using a lower dose of 20 mg daily for 6–8 weeks. The usual side effect of drying of the skin can be counteracted by the liberal use of moisturisers. The mechanism of action may be to reduce perifollicular cellular infiltration but the drug greatly curtails sebum production, which Fearfield has proposed as the putative autoantigen in EF.

PERMETHRIN
The commensal follicle mite, demodex, is a possible trigger antigen. A small series of patients have responded to topical 5% permethrin cream used daily on lesions and were able to control the disease eventually with one or two applications per week but upon cessation of treatment lesions recurred, but we have been unable repeat such success.

ANTIRETROVIRAL THERAPY
We have seen a marked decrease in the number of patients with EF in our clinics since the introduction of highly active antiretroviral therapy (HAART), although there have not been any reports of this in the literature. This is probably because patients’ CD4 counts usually rise above 250 x10^3/l on HAART.

OTHERS
Topical sodium cromoglycate, topical antibiotics, prednisolone, and dapsone have also been successfully used in some patients.

Contributors: SLS-D wrote the paper; LAF performed the research project and provided references and clinical and histopathological pictures; RCDS supervised the research project and the paper.